CG Oncology, Inc. CGON
CGON among the 162 companies we cover
Where it stands · the better end on the right. The band holds the middle half; the line is the median.
CGON and 9 peers, year by year
The 9 Health care companies closest to CGON in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.
Choose the peers
| Company | Year | Revenue | Sales growth | Operating margin | Net margin | FCF margin | Return on equity | Debt / equity |
|---|---|---|---|---|---|---|---|---|
| CGON CG Oncology, Inc. | FY2025 | $4.0M | +255% | n/m | n/m | n/m | −21.4% | 0.00 |
| SRRK Scholar Rock Holding Corp | FY2025 | $0 | - | - | - | - | −154.0% | 0.41 |
| CRSP CRISPR Therapeutics AG | FY2025 | $3.5M | −90.6% | n/m | n/m | n/m | −30.3% | 0.00 |
| IDYA IDEAYA Biosciences, Inc. | FY2025 | $218.7M | n/m | −72.8% | −52.0% | −33.6% | −11.1% | - |
| ROIV Roivant Sciences Ltd. | FY2026 | $8.3M | −71.6% | n/m | n/m | n/m | −6.6% | - |
| OCUL Ocular Therapeutix, Inc | FY2025 | $52.0M | −18.5% | −519.8% | −511.9% | −417.5% | −40.6% | 0.11 |
| RXRX Recursion Pharmaceuticals, Inc. | FY2025 | $74.7M | +26.9% | −867.9% | −863.4% | −506.5% | −57.0% | 0.02 |
| KYMR Kymera Therapeutics, Inc. | FY2025 | $39.2M | −16.7% | −891.1% | −794.0% | −597.6% | −19.7% | - |
| CYTK Cytokinetics Inc | FY2025 | $88.0M | +377% | −695.4% | −891.6% | −607.5% | n/m | n/m |
| AGIO Agios Pharmaceuticals, Inc. | FY2025 | $54.0M | +48.0% | −873.9% | −764.0% | −698.3% | −34.6% | - |
Each company, year by year
Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2023 to FY2025 · 10-K XBRL
Who rewrote the most
Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before
Revenue, FY2023 to FY2025
Revenue as reported in the 10-K.
| Company | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| CGON Dec | $204K | $1.1M | $4.0M |
| SRRK Dec | - | - | $0 |
| CRSP Dec | $371.2M | $37.3M | $3.5M |
| IDYA Dec | $23.4M | $7.0M | $218.7M |
| ROIV Mar | $31.5M | $32.7M | $29.1M |
| OCUL Dec | $58.4M | $63.7M | $52.0M |
| RXRX Dec | $44.6M | $58.8M | $74.7M |
| KYMR Dec | $78.6M | $47.1M | $39.2M |
| CYTK Dec | $7.5M | $18.5M | $88.0M |
| AGIO Dec | $26.8M | $36.5M | $54.0M |
| Peer median | $38.1M | $36.9M | $52.0M |
Sales growth, FY2023 to FY2025
Revenue against the fiscal year before.
| Company | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| CGON Dec | - | +458% | +255% |
| SRRK Dec | - | - | - |
| CRSP Dec | n/m | −89.9% | −90.6% |
| IDYA Dec | −54.1% | −70.1% | n/m |
| ROIV Mar | +10.8% | +3.8% | −11.2% |
| OCUL Dec | +13.5% | +9.0% | −18.5% |
| RXRX Dec | +11.9% | +32.0% | +26.9% |
| KYMR Dec | +67.8% | −40.1% | −16.7% |
| CYTK Dec | −92.0% | +145% | +377% |
| AGIO Dec | +88.4% | +36.1% | +48.0% |
| Peer median | +11.9% | +6.4% | −11.2% |
Operating margin, FY2023 to FY2025
Operating income / revenue.
Net margin, FY2023 to FY2025
Net income / revenue.
| Company | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| CGON Dec | n/m | n/m | n/m |
| SRRK Dec | - | - | - |
| CRSP Dec | −41.4% | −981.5% | n/m |
| IDYA Dec | −483.0% | n/m | −52.0% |
| ROIV Mar | n/m | n/m | −592.0% |
| OCUL Dec | −138.1% | −303.7% | −511.9% |
| RXRX Dec | −736.0% | −788.0% | −863.4% |
| KYMR Dec | −187.0% | −475.6% | −794.0% |
| CYTK Dec | n/m | n/m | −891.6% |
| AGIO Dec | n/m | n/m | −764.0% |
| Peer median | −187.0% | −631.8% | −764.0% |
Free cash flow, FY2023 to FY2025
Cash from operations minus capital spending.
| Company | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| CGON Dec | - | −$78.9M | −$132.5M |
| SRRK Dec | −$145.3M | −$201.0M | −$300.6M |
| CRSP Dec | −$269.8M | −$144.7M | −$345.9M |
| IDYA Dec | −$117.6M | −$251.4M | −$73.5M |
| ROIV Mar | −$856.1M | −$766.6M | −$844.0M |
| OCUL Dec | −$76.3M | −$136.0M | −$216.9M |
| RXRX Dec | −$299.7M | −$372.9M | −$378.3M |
| KYMR Dec | −$137.3M | −$207.3M | −$234.3M |
| CYTK Dec | −$415.7M | −$399.8M | −$534.8M |
| AGIO Dec | −$297.1M | −$391.5M | −$377.3M |
| Peer median | −$269.8M | −$251.4M | −$345.9M |
FCF margin, FY2023 to FY2025
Free cash flow / revenue.
Return on equity, FY2023 to FY2025
Net income / shareholders' equity at the year end.
| Company | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| CGON Dec | n/m | −12.0% | −21.4% |
| SRRK Dec | −73.6% | −66.8% | −154.0% |
| CRSP Dec | −8.2% | −19.0% | −30.3% |
| IDYA Dec | −18.2% | −25.9% | −11.1% |
| ROIV Mar | −87.2% | 72.9% | −3.7% |
| OCUL Dec | −88.6% | −61.4% | −40.6% |
| RXRX Dec | −70.8% | −44.8% | −57.0% |
| KYMR Dec | −37.2% | −26.8% | −19.7% |
| CYTK Dec | n/m | n/m | n/m |
| AGIO Dec | −43.4% | 43.7% | −34.6% |
| Peer median | −57.1% | −26.4% | −32.4% |
Debt / equity, FY2023 to FY2025
Total debt / shareholders' equity at the year end.
EPS (diluted), FY2023 to FY2025
Diluted earnings per share, on today's share count after splits.
| Company | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| CGON Dec | −$15.65 | −$1.41 | −$2.08 |
| SRRK Dec | −$1.99 | −$2.47 | −$3.29 |
| CRSP Dec | −$1.94 | −$4.34 | −$6.47 |
| IDYA Dec | −$1.96 | −$3.36 | −$1.28 |
| ROIV Mar | −$1.42 | $5.23 | −$0.24 |
| OCUL Dec | −$1.02 | −$1.22 | −$1.42 |
| RXRX Dec | −$1.58 | −$1.69 | −$1.44 |
| KYMR Dec | −$2.52 | −$2.98 | −$3.69 |
| CYTK Dec | −$5.45 | −$5.26 | −$6.54 |
| AGIO Dec | −$6.33 | $11.64 | −$7.12 |
| Peer median | −$1.96 | −$2.47 | −$3.29 |
Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out CGON and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more
Sources
Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.
Also
Financials: CGON's own statements, year by year. Compare: the whole peer group on one page.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CGON/export.csv") into a cell.